Clinical Nutrition For Cancer Care Market
The clinical nutrition sector specifically focused on cancer care is gaining traction as an essential component of supportive oncology treatment. With advancements in personalized medicine and a growing awareness of nutrition’s role in patient outcomes, this market is set to experience notable growth over the coming years. Below is an overview of the market size projections, key players, industry trends, and segmentation details shaping this evolving field.
Projected Expansion and Market Size of Clinical Nutrition for Cancer Care
The clinical nutrition for cancer care market is forecasted to grow steadily, reaching a valuation of $6.5 billion by 2030. This reflects a compound annual growth rate (CAGR) of 4.6%. Factors contributing to this increase include a stronger emphasis on tailored oncology nutrition, higher demand for protein-rich and immune-enhancing nutritional products, the rise of outpatient cancer treatment programs, and the expanding use of digital tools for nutrition monitoring. Additionally, there is a growing focus on improving patients’ quality of life during cancer therapy. Key trends anticipated to influence the market encompass broader adoption of personalized nutrition plans, increased use of specialized enteral and parenteral feeding solutions, integration of monitoring technologies, growth of home-based nutrition support, and targeted nutritional interventions addressing cancer-related symptoms.
Download a free sample of the clinical nutrition for cancer care market report:
https://www.thebusinessresearchcompany.com/report/clinical-nutrition-for-cancer-care-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR
Leading Companies Influencing the Clinical Nutrition for Cancer Care Market
Several prominent firms dominate this niche market, including Abbott Nutrition, Baxter International Inc., B Braun Melsungen AG, Nestle Health Science S A, Danone Nutricia, Hormel Health Labs, Evonik Industries AG, Otsuka Holdings Co Ltd, Koninklijke DSM N V, Glanbia plc, Meiji Holdings Company Ltd, Victus Inc., Global Health Products Inc., Fresenius Kabi AG, Perrigo Company plc, Arla Foods Ingredients Group P S, Kerry Group plc, Lonza Group AG, Ajinomoto Co Inc., Yakult Honsha Co Ltd, Rousselot BV, Tate Lyle plc, ADM Human Nutrition, Vitaflo International Ltd, Smartfish AS, and Medtrition Inc.
A significant development occurred in January 2024 when Danone S.A., a French food products company, partnered with Resilience, a U.S.-based digital oncology firm, to create an innovative nutrition and oncology module. This collaboration aims to enhance nutritional care for cancer patients by addressing malnutrition-a condition affecting up to 70% of individuals undergoing cancer treatment. Resilience provides clinical nutrition support within its digital oncology platform, strengthening patient management.
Emerging Trends in the Clinical Nutrition for Cancer Care Industry
The clinical nutrition market for cancer care is also impacted by innovations seen in related medical technology sectors. For instance, manufacturers of drug-eluting balloon catheters are focusing on next-generation products that deliver improved outcomes. In March 2024, Boston Scientific Corporation announced FDA approval for its AGENT Drug-Coated Balloon, the first of its kind in the U.S. designed to treat in-stent restenosis by delivering a paclitaxel coating directly to affected vessel walls. Clinical trials demonstrated a 49% reduction in heart attack risk at treated sites and showed a low incidence of adverse events. Such advancements highlight the broader trend of integrating cutting-edge therapeutic technologies into oncology care.
The clinical nutrition sector specifically focused on cancer care is gaining traction as an essential component of supportive oncology treatment. With advancements in personalized medicine and a growing awareness of nutrition’s role in patient outcomes, this market is set to experience notable growth over the coming years. Below is an overview of the market size projections, key players, industry trends, and segmentation details shaping this evolving field.
Projected Expansion and Market Size of Clinical Nutrition for Cancer Care
The clinical nutrition for cancer care market is forecasted to grow steadily, reaching a valuation of $6.5 billion by 2030. This reflects a compound annual growth rate (CAGR) of 4.6%. Factors contributing to this increase include a stronger emphasis on tailored oncology nutrition, higher demand for protein-rich and immune-enhancing nutritional products, the rise of outpatient cancer treatment programs, and the expanding use of digital tools for nutrition monitoring. Additionally, there is a growing focus on improving patients’ quality of life during cancer therapy. Key trends anticipated to influence the market encompass broader adoption of personalized nutrition plans, increased use of specialized enteral and parenteral feeding solutions, integration of monitoring technologies, growth of home-based nutrition support, and targeted nutritional interventions addressing cancer-related symptoms.
Download a free sample of the clinical nutrition for cancer care market report:
https://www.thebusinessresearchcompany.com/report/clinical-nutrition-for-cancer-care-global-market-report?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Apr_PR
Leading Companies Influencing the Clinical Nutrition for Cancer Care Market
Several prominent firms dominate this niche market, including Abbott Nutrition, Baxter International Inc., B Braun Melsungen AG, Nestle Health Science S A, Danone Nutricia, Hormel Health Labs, Evonik Industries AG, Otsuka Holdings Co Ltd, Koninklijke DSM N V, Glanbia plc, Meiji Holdings Company Ltd, Victus Inc., Global Health Products Inc., Fresenius Kabi AG, Perrigo Company plc, Arla Foods Ingredients Group P S, Kerry Group plc, Lonza Group AG, Ajinomoto Co Inc., Yakult Honsha Co Ltd, Rousselot BV, Tate Lyle plc, ADM Human Nutrition, Vitaflo International Ltd, Smartfish AS, and Medtrition Inc.
A significant development occurred in January 2024 when Danone S.A., a French food products company, partnered with Resilience, a U.S.-based digital oncology firm, to create an innovative nutrition and oncology module. This collaboration aims to enhance nutritional care for cancer patients by addressing malnutrition-a condition affecting up to 70% of individuals undergoing cancer treatment. Resilience provides clinical nutrition support within its digital oncology platform, strengthening patient management.
Emerging Trends in the Clinical Nutrition for Cancer Care Industry
The clinical nutrition market for cancer care is also impacted by innovations seen in related medical technology sectors. For instance, manufacturers of drug-eluting balloon catheters are focusing on next-generation products that deliver improved outcomes. In March 2024, Boston Scientific Corporation announced FDA approval for its AGENT Drug-Coated Balloon, the first of its kind in the U.S. designed to treat in-stent restenosis by delivering a paclitaxel coating directly to affected vessel walls. Clinical trials demonstrated a 49% reduction in heart attack risk at treated sites and showed a low incidence of adverse events. Such advancements highlight the broader trend of integrating cutting-edge therapeutic technologies into oncology care.
Market Segmentation and Forecast by Type, Cancer, Age, and Sales Channels
This report classifies the clinical nutrition for cancer care market into multiple segments for a detailed understanding:
1) By Type:
– Oral Nutrition
– Parenteral Nutrition
– Enteral Feeding Formulas
2) By Cancer Type:
– Head and Neck Cancer
– Stomach and Gastrointestinal Cancers
– Blood Cancer
– Breast Cancer
– Lung Cancer
– Other Cancer Types
3) By Age Group:
– Adult
– Pediatric
4) By Sales Channel:
– Online
– Retail
– Institutional Sales
Further breakdown includes:
– Oral Nutrition subcategories such as protein-rich, carbohydrate-rich, fat-rich, vitamin and mineral, caloric, and fiber-enriched supplements.
– Parenteral Nutrition subsegments covering amino acids, carbohydrates, lipids, electrolytes and micronutrients, intravenous fat emulsions, trace elements, and vitamins.
– Enteral Feeding Formulas subtypes like standard, high-protein, high-calorie, diabetic, elemental, and specialized formulas.
This segmentation reflects the diverse needs and solutions within clinical nutrition for cancer care, providing a comprehensive outlook for stakeholders and investors looking to understand market dynamics.
Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
